200
Participants
Start Date
November 14, 2023
Primary Completion Date
July 31, 2028
Study Completion Date
July 31, 2028
Cevostamab
"Substudy 2: Cevostamab will be administered intravenously (IV) on a 28-day cycle, up to a total of 13 cycles.~Substudy 4: Cevostamab will be administered by IV on a 21-day cycle, up to a total of 17 cycles."
Lenalidomide
Lenalidomide will be administered PO on days 1-21 of a 28-day cycle.
Tocilizumab
Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
Iberdomide
Iberdomide will be administered PO on days 1-14 of a 21-day cycle.
Dexamethasone
Dexamethasone will be administered on Days 2 and 8 of Cycles 1-3.
RECRUITING
Prince of Wales Hospital, Randwick
RECRUITING
St Vincent's Hospital Melbourne, Fitzroy
RECRUITING
Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II, Hamburg
RECRUITING
Fundacion Jimenez Diaz, Madrid
RECRUITING
IUCT Oncopole, Toulouse
RECRUITING
Hopital Bretonneau, Tours
RECRUITING
Hospital Clinico Universitario de Valencia, Valencia
RECRUITING
CHU Lyon Sud - Service Hématologie, Pierre-Bénite
WITHDRAWN
IGR, Villejuif
RECRUITING
Universitätsklinikum Leipzig - Klinik und Poliklinik für Hämatologie, Leipzig
RECRUITING
Uniwersyteckie Centrum Kliniczne, Gda?sk
RECRUITING
Oddzial Kliniczny Hematologii SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie, Olsztyn
RECRUITING
Uniwersytecki Szpital Kliniczny w Poznaniu, Późna
RECRUITING
Severance Hospital, Yonsei University Health System, Seoul
RECRUITING
Samsung Medical Center, Seoul
RECRUITING
Hospital Universitari Germans Trias i Pujol, Badalona
Hoffmann-La Roche
INDUSTRY